The latest price target for Journey Medical (NASDAQ:DERM) was reported by Lake Street on September 6, 2024. The analyst firm set a price target for $9.00 expecting DERM to rise to within 12 months (a possible 72.08% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Journey Medical (NASDAQ:DERM) was provided by Lake Street, and Journey Medical initiated their buy rating.

There is no last upgrade for Journey Medical

There is no last downgrade for Journey Medical.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Journey Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Journey Medical was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

While ratings are subjective and will change, the latest Journey Medical (DERM) rating was a initiated with a price target of $0.00 to $9.00. The current price Journey Medical (DERM) is trading at is $5.23, which is within the analyst’s predicted range.